An ambispective, observational, multi-center study of first-line Lorlatinib in patients with ALK-positive non-small cell lung cancer in Korea (Lorlatinib NIS)

First published 06/11/2026

Last updated 06/11/2026

EU PAS number:

EUPAS1000001141

Study

Planned

Download as PDF

Documents

Study protocol

No information provided.

Study results

No information provided.

Study report

No information provided.

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

No information provided.

An ambispective, observational, multi-center study of first-line Lorlatinib in patients with ALK-positive non-small cell lung cancer in Korea (Lorlatinib NIS)

Secondary tabs

Share this page